Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.

Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW.

JAMA Oncol. 2018 Jun 21. doi: 10.1001/jamaoncol.2018.1888. [Epub ahead of print]

PMID:
29931076
2.

Prescription Drug Monitoring Programs and Pharmacist Orientation Toward Dispensing Controlled Substances.

Fendrich M, Bryan JK, Hooyer K.

Subst Use Misuse. 2018 Jul 3;53(8):1324-1330. doi: 10.1080/10826084.2017.1408650. Epub 2018 Jan 3.

PMID:
29297725
3.

Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.

Shayan G, Kansy BA, Gibson SP, Srivastava RM, Bryan JK, Bauman JE, Ohr J, Kim S, Duvvuri U, Clump DA, Heron DE, Johnson JT, Hershberg RM, Ferris RL.

Clin Cancer Res. 2018 Jan 1;24(1):62-72. doi: 10.1158/1078-0432.CCR-17-0357. Epub 2017 Oct 23.

PMID:
29061643
4.

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.

Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G.

Ann Oncol. 2017 May 1;28(5):996-1004. doi: 10.1093/annonc/mdx049.

5.

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.

Chow LQM, Morishima C, Eaton KD, Baik CS, Goulart BH, Anderson LN, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Disis ML, Martins RG.

Clin Cancer Res. 2017 May 15;23(10):2442-2450. doi: 10.1158/1078-0432.CCR-16-1934. Epub 2016 Nov 3.

6.

Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337).

Dietsch GN, Randall TD, Gottardo R, Northfelt DW, Ramanathan RK, Cohen PA, Manjarrez KL, Newkirk M, Bryan JK, Hershberg RM.

Clin Cancer Res. 2015 Dec 15;21(24):5445-52. doi: 10.1158/1078-0432.CCR-15-0578. Epub 2015 Jul 7.

7.

An Evidence-Based Systematic Review of Goji (Lycium spp.) by the Natural Standard Research Collaboration.

Ulbricht C, Bryan JK, Costa D, Culwell S, Giese N, Isaac R, Nummy K, Pham T, Rapp C, Rusie E, Weissner W, Windsor RC, Woods J, Zhou S.

J Diet Suppl. 2015 Jun;12(2):184-240. doi: 10.3109/19390211.2014.904128. Epub 2014 May 7. Review.

PMID:
24806435
8.

An evidence-based systematic review of active hexose correlated compound (AHCC) by the Natural Standard Research Collaboration.

Ulbricht C, Brigham A, Bryan JK, Catapang M, Chowdary D, Costa D, Culwell S, D'Auria D, Giese N, Iovin R, Isaac R, Juturu V, Liu A, Mintzer M, Rusie E, Shaffer M, Windsor RC.

J Diet Suppl. 2013 Sep;10(3):264-308. doi: 10.3109/19390211.2013.822631. Epub 2013 Aug 9. Review.

PMID:
23931762
9.

An evidence-based systematic review of annatto (Bixa orellana L.) by the Natural Standard Research Collaboration.

Ulbricht C, Windsor RC, Brigham A, Bryan JK, Conquer J, Costa D, Giese N, Guilford J, Higdon ER, Holmes K, Isaac R, Jingst S, Kats J, Peery L, Rusie E, Savinainen A, Schoen T, Stock T, Tanguay-Colucci S, Weissner W.

J Diet Suppl. 2012 Mar;9(1):57-77. doi: 10.3109/19390211.2012.653530. Review. No abstract available.

PMID:
22432803
10.

An evidence-based systematic review of cinnamon (Cinnamomum spp.) by the Natural Standard Research Collaboration.

Ulbricht C, Seamon E, Windsor RC, Armbruester N, Bryan JK, Costa D, Giese N, Gruenwald J, Iovin R, Isaac R, Serrano JM, Tanguay-Colucci S, Weissner W, Yoon H, Zhang J.

J Diet Suppl. 2011 Dec;8(4):378-454. doi: 10.3109/19390211.2011.627783. Review.

PMID:
22432776
11.

An evidence-based systematic review of amylase inhibitors by the Natural Standard Research Collaboration.

Ulbricht C, Bryan JK, Conquer J, Costa D, Stock T, Tanguay-Colucci S, Weissner W.

J Diet Suppl. 2010 Mar;7(1):78-95. doi: 10.3109/19390210903535043. Review.

PMID:
22435576
12.

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.

Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S, Stone D, Axworthy D, Fisher D, Reno J.

Cancer Biother Radiopharm. 2000 Feb;15(1):15-29.

PMID:
10740649
13.
14.
15.

Characterization of ligand-induced states of maize homoserine dehydrogenase.

Krishnaswamy S, Bryan JK.

Arch Biochem Biophys. 1983 Nov;227(1):210-24.

PMID:
6357097
16.

Ligand-induced interconversions of maize homoserine dehydrogenase among different states.

Krishnaswamy S, Bryan JK.

Arch Biochem Biophys. 1983 Apr 15;222(2):449-63.

PMID:
6405698
17.
19.

Comparison of sensitive and desensitized forms of maize homoserine dehydrogenase.

Dicamelli CA, Bryan JK.

Plant Physiol. 1980 Feb;65(2):176-83.

20.
21.

Molecular weights of protein multimers from polyacrylamide gel electrophoresis.

Bryan JK.

Anal Biochem. 1977 Apr;78(2):513-9. No abstract available.

PMID:
851223
25.

Isolation and characterization of a lysine-sensitive aspartokinase from a multicellular plant.

Bryan PA, Cawley RD, Brunner CE, Bryan JK.

Biochem Biophys Res Commun. 1970 Dec 9;41(5):1211-7. No abstract available.

PMID:
5483624
26.
27.

Studies on the catalytic and regulatory properties of homoserine dehydrogenase of Zea mays roots.

Bryan JK.

Biochim Biophys Acta. 1969 Feb 11;171(2):205-16. No abstract available.

PMID:
4388077

Supplemental Content

Loading ...
Support Center